Baricitinib 2 MG ( DrugBank: Baricitinib )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
| 53 | シェーグレン症候群 | 1 |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05660655 (ClinicalTrials.gov) | September 1, 2022 | 13/12/2022 | Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis | Efficacy and Safety of Baricitinib in Different Doses for the Treatment of Moderate to Severe Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Baricitinib 4 MG;Drug: Baricitinib 2 MG | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | NULL | Recruiting | 18 Years | N/A | All | 94 | Phase 4 | Bangladesh |
53. シェーグレン症候群
臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04916756 (ClinicalTrials.gov) | January 16, 2020 | 1/6/2021 | A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients | A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients | Sjogren's Syndrome | Drug: Baricitinib 2 MG | Peking Union Medical College Hospital | NULL | Completed | 18 Years | N/A | All | 11 | Phase 1/Phase 2 | China |